• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NLTX

NLTX

Neoleukin Therapeutics, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD3.49

+0.05 (+1.45%)

Company Profile

CEO

Donna M. Cochener-Metcalfe

IPO Date

2014-03-07

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.45

Prev. Close

$3.44

Day Low

$3.42

Day High

$3.59

52W Low

$3.42

52W High

$18.80

Market Cap

$0.01B

Volume

0.11M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

22.2%

Avg Negative

21.7%

Avg Neutral

56.3%

News Feed

Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update

GlobeNewsWire·5/12/2021·↑ positive

Neoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/25/2021·↓ negative

Neoleukin Therapeutics Announces Year End 2020 Financial Results

GlobeNewsWire·
3/25/2021
·↑ positive

Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

GlobeNewsWire·3/2/2021·↑ positive

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

GlobeNewsWire·2/5/2021·↑ positive

Neoleukin Therapeutics: De Novo Protein Design Platform

Seeking Alpha·2/3/2021·↓ negative

SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC

Newsfile Corp·1/25/2021·↑ positive

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX

Newsfile Corp·1/20/2021·↓ negative

Why Neoleukin Therapeutics Stock Is Down Today

The Motley Fool·1/8/2021·↓ negative

Aquinox (NLTX) Moves to Buy: Rationale Behind the Upgrade

Zacks Investment Research·1/8/2021·↑ positive